Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Precision Therapeutics Reports Third Quarter 2018 Financial Results
MINNEAPOLIS , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today financial results for the three and nine months ended
View HTML
Toggle Summary Precision Therapeutics to Hold Business Update Conference Call on November 14, 2018
MINNEAPOLIS , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that management will report its financial results for the
View HTML
Toggle Summary Precision Therapeutics Secures Rights to Novel Technology Designed To Develop Drugs That Target Specific Cancer by Its Mutation
MINNEAPOLIS , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today that it has acquired rights to technology for the proprietary
View HTML
Toggle Summary Filing under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934 Filing by: Precision Therapeutics Inc.: SEC File Nos. 001-36790; and 333-221966
Precision Therapeutics Files Form S-4 Regarding Proposed Merger with Helomics Holding Corporation MINNEAPOLIS , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine
View HTML
Toggle Summary Precision Therapeutics Continues to Build World Class Scientific Advisory Board with Appointment of Hector J. Gomez, MD, PhD
MINNEAPOLIS , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has appointed Dr. Hector J. Gomez , President & CEO, Co-Founder of GLG
View HTML
Toggle Summary Precision Therapeutics’ Skyline Medical Division Signs International Distribution Agreement with India-based Prenit World
MINNEAPOLIS , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) is pleased to announce that its Skyline Medical division, producer of the FDA -approved and CE-marked  STREAMWAY® System  for automated, direct-to-drain medical fluid
View HTML
Toggle Summary Precision Therapeutics Secures First STREAMWAY System Sale in Europe
MINNEAPOLIS , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”) is pleased to announce it has secured its first European sale of the STREAMWAY System® , an automated, direct-to-drain medical fluid disposal system sold by the Company’s
View HTML
Toggle Summary Dr. Bob Murphy, Head of Computational Biology at Carnegie Mellon University, Joins Precision Therapeutics’ Scientific Advisory Board
MINNEAPOLIS , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has appointed Dr. Robert Murphy to its Scientific Advisory Board . Dr.
View HTML
Toggle Summary Precision Therapeutics Bolsters Scientific Advisory Board with the Appointment of Dr. Paul Kornblith
MINNEAPOLIS , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has bolstered its Scientific Advisory Board with the appointment of Dr.
View HTML
Toggle Summary Precision Therapeutics Appoints Dr. Amelia Warner to Scientific Advisory Board
MINNEAPOLIS , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, is pleased to announce that Dr.
View HTML